Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Guadecitabine |
Synonyms | |
Therapy Description |
Guadecitabine (SGI-110) is a dinucleotide comprised of decitabine and deoxyguanosine, which inhibits DNA methylation, potentially resulting in decreased tumor cell growth (PMID: 20442312, PMID: 17616700, PMID: 32655143). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Guadecitabine | S110|SGI-110 | DNMT inhibitor (Pan) 5 | Guadecitabine (SGI-110) is a dinucleotide comprised of decitabine and deoxyguanosine, which inhibits DNA methylation, potentially resulting in decreased tumor cell growth (PMID: 20442312, PMID: 17616700, PMID: 32655143). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03603964 | Phase II | Guadecitabine | Guadecitabine Extension Study | Terminated | USA | ITA | ESP | DNK | CAN | AUT | 3 |
NCT03165721 | Phase II | Guadecitabine | A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer | Terminated | USA | 0 |
NCT02131597 | Phase II | Guadecitabine | SGI-110 in Higher Risk Myelodysplastic Syndrome (MDS) | Completed | USA | 0 |
NCT02348489 | Phase III | Guadecitabine Cytarabine Azacitidine Decitabine | SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction | Completed | USA | SWE | ROU | POL | NLD | ITA | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BGR | BEL | AUT | AUS | 5 |
NCT02429466 | Phase I | Cisplatin Guadecitabine | Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors | Completed | USA | 0 |
NCT03308396 | Phase Ib/II | Durvalumab + Guadecitabine Guadecitabine | Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer | Active, not recruiting | USA | 0 |
NCT01966289 | Phase I | Cyclophosphamide Guadecitabine GVAX colorectal cancer vaccine | SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC) | Completed | USA | 0 |
NCT02907359 | Phase III | Cytarabine Guadecitabine | Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs | Completed | USA | SWE | POL | ITA | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BEL | 2 |
NCT02684162 | Phase II | Guadecitabine | SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT) | Completed | USA | 0 |
NCT03075826 | Phase II | Guadecitabine | A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms | Completed | USA | 0 |
NCT02920008 | Phase III | Decitabine Azacitidine Cytarabine Guadecitabine | Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia | Completed | USA | SWE | POL | ITA | HUN | GBR | FRA | ESP | DNK | DEU | CAN | BEL | 3 |
NCT02096055 | Phase II | Cladribine Guadecitabine Idarubicin | 4-Arm Phase II Study of SGI-110 in Elderly Acute Myeloid Leukemia (AML) | Completed | USA | 0 |